Literature DB >> 3931464

Pharmacokinetics of glyburide.

J G Pearson.   

Abstract

The pharmacokinetics of glyburide can be described by a two-compartment open model. Terminal-phase descriptions are formulation-dependent and are complicated by apparent food-associated mobilization of drug from the stomach. Some researchers indicate a possible third (or deep) compartment, but this appears to be an artifact of a nonspecific drug assay. Although no accumulation has been observed in short-term studies, further investigation of the possibility of drug accumulation with long-term therapy is needed. Distribution of glyburide is affected by high affinity for serum albumin (99 percent bound), and elimination of the drug appears to be evenly divided between biliary and renal routes. The biologic half-life of glyburide is not significantly correlated with renal function in subjects with creatinine clearances of 30 ml/minute/1.7 m2 or more. Gradations in disease state, multiple sites of sulfonylurea action, and inter-patient variability have made it difficult to relate biologic response to glyburide serum levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931464     DOI: 10.1016/s0002-9343(85)80010-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

3.  Exaggerated impact of ATP-sensitive K(+) channels on afferent arteriolar diameter in diabetes mellitus.

Authors:  Hideki Ikenaga; Joseph P Bast; Rachel W Fallet; Pamela K Carmines
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

4.  Tempol prevents altered K(+) channel regulation of afferent arteriolar tone in diabetic rat kidney.

Authors:  Carmen M Troncoso Brindeiro; Pascale H Lane; Pamela K Carmines
Journal:  Hypertension       Date:  2012-01-17       Impact factor: 10.190

5.  The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog.

Authors:  D W Landry; J A Oliver
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 6.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.

Authors:  L A Jaber; E J Antal; R L Slaughter; I R Welshman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

Authors:  G Leibowitz; E Cerasi
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

Review 9.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 10.  Prescription drugs and mitochondrial metabolism.

Authors:  Cameron A Schmidt
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.